Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 40: 889-894, 1994;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nishimura, C.
Right arrow Articles by Urakami, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nishimura, C.
Right arrow Articles by Urakami, T.

Clinical Chemistry, Vol 40, 889-894, Copyright © 1994 by American Association for Clinical Chemistry

Enzyme immunoassay for erythrocyte aldose reductase

C Nishimura, Y Hamada, T Tachikawa, T Ishikawa, T Gui, J Tsubouchi, N Hotta, T Tanimoto and T Urakami
Department of Pediatric Pharmacology, National Children's Medical Research Center, Tokyo, Japan.

This two-site immunoassay measures erythrocyte aldose reductase by using monoclonal and polyclonal antibodies to recombinant human enzyme. Total incubation time is 2.5 h, and the limit of detection is < 0.05 microgram/L. Analytical recovery tested with blood samples from healthy and diabetic individuals was 101-106%. Average CVs within and between assays were 3.7% and 4.8%, respectively. The enzyme content determined by this system correlated well with the activity of aldose reductase isolated from the same erythrocyte preparations. The amount of erythrocyte aldose reductase per milligram of hemoglobin was higher in women than in men (P < 0.001), but no significant correlation was observed between the amount of enzyme and the age of the individuals. This assay method should provide useful clinical information to optimize administration of aldose reductase inhibitors for effective prevention and treatment of diabetic complications.


The following articles in journals at HighWire Press have cited this article:


Home page
 IOVSHome page
N. Oishi, S. Morikubo, Y. Takamura, E. Kubo, S. Tsuzuki, T. Tanimoto, and Y. Akagi
Correlation between Adult Diabetic Cataracts and Red Blood Cell Aldose Reductase Levels
Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 2061 - 2064.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
N Oishi, E Kubo, Y Takamura, K Maekawa, T Tanimoto, and Y Akagi
Correlation between erythrocyte aldose reductase level and human diabetic retinopathy
Br J Ophthalmol, December 1, 2002; 86(12): 1363 - 1366.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Gui, H.-F. Lin, D.-Y. Jin, M. Hoffman, D. L. Straight, H. R. Roberts, and D. W. Stafford
Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo
Blood, June 17, 2002; 100(1): 153 - 158.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
C. Yabe-Nishimura
Aldose Reductase in Glucose Toxicity: A Potential Target for the Prevention of Diabetic Complications
Pharmacol. Rev., March 1, 1998; 50(1): 21 - 34.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Association for Clinical Chemistry.